BEDMINSTER, N.J., May 16 /PRNewswire-FirstCall/ --
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, announced today that the Company will
report its fiscal 2002 fourth-quarter and year-end financial results on
Thursday, May 23, 2002 at 7:30 a.m. Eastern Daylight Time, and hold a
conference call at 10:00 a.m. Eastern Daylight Time.
To participate in the call via telephone, please dial 888-224-3260, or to
hear the call live over the Internet, visit http://www.bioject.com. A conference
call replay will be available until May 30, 2002. To listen to the replay,
please dial 800-428-6051, replay pass code 243361.
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
manufacturing facilities in Portland, Oregon, is an innovative developer and
manufacturer of needle-free drug delivery systems. Needle-free injection
works by forcing medication at high speed through a tiny orifice held against
the skin. This creates a fine stream of high-pressure fluid penetrating the
skin and depositing medication in the tissue beneath. The company is focused
on developing mutually beneficial agreements with leading pharmaceutical and
biotechnology companies. Bioject's strategic partners include Serono and
Alkermes.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Readers of this press release are referred to the company's
filings with the Securities and Exchange Commission, including the company's
reports on Forms 10-K and Forms 10-Q for further discussions of factors that
could affect future results. Forward-looking statements are based on the
estimates and opinions of management on the date the statements are made. The
Company assumes no obligation to update forward-looking statements if
conditions or management's estimates or opinions should change.
For more information about Bioject, visit: http://www.bioject.com.
SOURCE Bioject Medical Technologies, Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5103,
or cheer@bioject.com
|
